Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma

“Time-limited epcoritamab with [lenalidomide plus rituximab] resulted in durable responses that were deep, with an overall response rate of 95% and a complete response rate of 88%.”

Lori A. Leslie, MD, director of the Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs at John Theurer Cancer Center at Hackensack Meridian Health and an assistant professor at the Hackensack Meridian School of Medicine, discussed 3-year efficacy findings from arm 6 of the phase 1b/2 EPCORE NHL-2 trial (NCT04663347) investigating epcoritamab-bysp (Epkinly) plus rituximab (Rituxan) and lenalidomide (Revlimid) in patients with previously untreated follicular lymphoma.